Vinpocetine inhibits NF-κB-dependent inflammation via an IKK-dependent but PDE-independent mechanism

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 21, 2010, Pages 9795-9800

  Jeon, Kye Im ^a   Xu, Xiangbin ^a   Aizawa, Toru ^b   Lim, Jae Hyang ^a   Jono, Hirofumi ^a   Kwon, Dong Seok ^c   Abe, Jun Ichi ^a   Berk, Bradford C ^a   Li, Jian Dong ^a   Yan, Chen ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Seoul National University   (South Korea)

Author keywords

IKK; Inflammation; NF B; Vinpocetine

Indexed keywords

I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 2; TUMOR NECROSIS FACTOR ALPHA; VINPOCETINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ADHESION; CHEMOTAXIS; CONTROLLED STUDY; ENDOTHELIUM CELL; EPITHELIUM CELL; MACROPHAGE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CALCIUM; CELL ADHESION; CELLS, CULTURED; CHEMOTAXIS; HUMANS; I-KAPPA B KINASE; MICE; MICE, INBRED C57BL; MONOCYTES; NF-KAPPA B; PHOSPHORIC DIESTER HYDROLASES; PNEUMONIA; TUMOR NECROSIS FACTOR-ALPHA; VINCA ALKALOIDS;

EID: 77953103987     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0914414107     Document Type: Article

References (28)

1. Libby P (2002) Inflammation in atherosclerosis. Nature 420:868-874.
2. Tetley TD (2005) Inflammatory cells and chronic obstructive pulmonary disease. Current Drug Target-Inflammation & Allergy 4:607-618.
3. Okamoto H (2006) Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355:2047-2048.
4. Kleiman A, Tuckermann JP (2007) Glucocorticoid receptor action in beneficial and side effects of steroid therapy: Lessons from conditional knockout mice. Mol Cell Endocrinol 275:98-108.
5. Manson SC, Brown RE, Cerulli A, Vidaurre CF (2009) The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 103:975-994.
6. Rothwarf DM, Karin M (1999) The NF-kappa B activation pathway: A paradigm in information transfer from membrane to nucleus. Sci STKE 1999:RE1-16.
7. Ghosh S, May MJ, Kopp EB (1998) NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225-260.
8. Mercurio F, et al. (1997) IKK-1 and IKK-2: Cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 278:860-866.
9. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M (1997) The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 91:243-252.
10. Zandi E, Chen Y, Karin M (1998) Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: Discrimination between free and NF-kappaB-bound substrate. Science 281: 1360-1363. (Pubitemid 28406830)
11. Lee FS, Peters RT, Dang LC, Maniatis T (1998) MEKK1 activates both IkappaB kinase alpha and IkappaB kinase beta. Proc Natl Acad Sci USA 95:9319-9324. (Pubitemid 128625311)
12. Yamaoka S, et al. (1998) Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell 93:1231-1240.
13. Rothwarf DM, Zandi E, Natoli G, Karin M (1998) IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 395:297-300.
14. Mercurio F, et al. (1999) IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex. Mol Cell Biol 19:1526-1538. (Pubitemid 29046894)
15. Bagoly E, Fehér G, Szapáry L (2007) The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies. OrvHetil 148:1353-1358 (in Hungarian).
16. Tamaki N, Matsumoto S (1985) Agents to improve cerebrovascular circulation and cerebral metabolism-vinpocetine. Nippon Rinsho 43:376-378 (in Japanese).
17. Szobor A, Klein M (1976) Ethyl apovincaminate therapy in neurovascular diseases. Arzneim-Forsch 26 (10a):1984-1989.
18. Bönöczk P, et al. (2000) Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine. Brain Res Bull 53:245-254.
19. Balestreri R, Fontana L, Astengo F (1987) A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc 35:425-430. (Pubitemid 17070608)
20. Ishinaga H, et al. (2007) TGF-beta induces p65 acetylation to enhance bacteria-induced NF-kappaB activation. EMBO J 26:1150-1162.
21. Nemoto S, DiDonato JA, Lin A (1998) Coordinate regulation of IkappaB kinases by mitogen-activated protein kinase kinase kinase 1 and NF-kappaB-inducing kinase. Mol Cell Biol 18:7336-7343. (Pubitemid 28533053)
22. Hagiwara M, Endo T, Hidaka H (1984) Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem Pharmacol 33:453-457.
23. Nagel DJ, et al. (2006) Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circ Res 98:777-784.
24. Kaneko S, Takahashi H, Satoh M (1990) The use of Xenopus oocytes to evaluate drugs affecting brain Ca2+ channels: Effects of bifemelane and several nootropic agents. Eur J Pharmacol 189:51-58.
25. Tretter L, Adam-Vizi V (1998) The neuroprotective drug vinpocetine prevents veratridine-induced [Na+]i and [Ca2+]i rise in synaptosomes. NeuroReport 9:1849-1853.
26. Dunkern TR, Hatzelmann A (2007) Characterization of inhibitors of phosphodiesterase 1C on a human cellular system. FEBS J 274:4812-4824.
27. Burnouf C, Pruniaux MP (2002) Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr PharmDes 8:1255-1296.
28. Adám-Vizi V (2000) Neuroprotective effect of sodium channel blockers in ischemia: The pathomechanism of early ischemic dysfunction. Orv Hetil, 141:1279-1286 (in Hungarian).